Inhibition of p38 mitogen-activated protein kinase attenuates butyrate-induced intestinal barrier impairment in a Caco-2 cell monolayer model

J Pediatr Gastroenterol Nutr. 2014 Aug;59(2):264-9. doi: 10.1097/MPG.0000000000000369.

Abstract

Objectives: Butyrate is well known to induce apoptosis in differentiating intestinal epithelial cells. The present study was designed to examine the role of p38 mitogen-activated protein kinase (MAPK) in butyrate-induced intestinal barrier impairment.

Methods: The intestinal barrier was determined by measuring the transepithelial electrical resistance (TER) in a Caco-2 cell monolayer model. The permeability was determined by measuring transepithelial passage of fluorescein isothiocyanate-conjugated inulin (inulin-FITC). The morphology of the monolayers was examined with scanning electron microscopy. The apoptosis status was determined by annexin V-FITC labeling and flow cytometry. The activity of p38 MAPK was determined by the phosphorylation status of p38 with Western blotting.

Results: Butyrate at 5 mM increases the apoptosis rate of Caco-2 cells and induces impairment of intestinal barrier functions as determined by decreased TER and increased inulin-FITC permeability. Butyrate treatment activates p38 MAPK in a concentration- and time-dependent manner. SB203580, a specific p38 inhibitor, inhibits butyrate-induced Caco-2 cell apoptosis. Treatment of SB203580 significantly attenuates the butyrate-induced impairment of barrier functions in the Caco-2 cell monolayer model.

Conclusions: p38 MAPK can be activated by butyrate and is involved in the butyrate-induced apoptosis and impairment of intestinal barrier function. Inhibition of p38 MAPK can significantly attenuate butyrate-induced intestinal barrier dysfunction.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Annexin A5 / metabolism
  • Apoptosis* / drug effects
  • Butyrates / adverse effects*
  • Caco-2 Cells
  • Electric Impedance
  • Enzyme Inhibitors / pharmacology
  • Fluorescein-5-isothiocyanate / metabolism
  • Humans
  • Imidazoles / pharmacology
  • Intestinal Absorption* / drug effects
  • Intestinal Diseases / enzymology*
  • Intestinal Diseases / metabolism
  • Intestinal Mucosa / enzymology*
  • Intestinal Mucosa / metabolism
  • Inulin / metabolism
  • Permeability
  • Phosphorylation
  • Pyridines / pharmacology
  • p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • p38 Mitogen-Activated Protein Kinases / metabolism*

Substances

  • Annexin A5
  • Butyrates
  • Enzyme Inhibitors
  • Imidazoles
  • Pyridines
  • Inulin
  • p38 Mitogen-Activated Protein Kinases
  • Fluorescein-5-isothiocyanate
  • SB 203580